ReviewCold Spring Harbor symposia on quantitative biology2005
Oncogenes come of age.
Review in Cold Spring Harbor symposia on quantitative biology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Cancer Genes: Origins and Directions.Viruses · 2026Review
- Is cancer the result of uncontrolled cellular growth? a glance into the tumorigenic process.Cancer cell international · 2026Review
- Metabolic memory underlying minimal residual disease in breast cancer.Molecular systems biology · 2021Article
- Micromanaging aerobic respiration and glycolysis in cancer cells.Molecular metabolism · 2019Review
- Facets of Communication: Gap Junction Ultrastructure and Function in Cancer Stem Cells and Tumor Cells.Cancers · 2019Review
- Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.eLife · 2018Article
- O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle.Journal of bioenergetics and biomembranes · 2018Review
- Otto Warburg's contributions to current concepts of cancer metabolism.Nature reviews. Cancer · 2011Review
- Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.Nature biotechnology · 2010Article
- The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function.Cell cycle (Georgetown, Tex.) · 2009Article
- Article
- Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction.Genes & development · 2009Article
- Defining the blueprint of the cancer genome.Carcinogenesis · 2008Review
- A large animal model to evaluate the effects of Hsp90 inhibitors for the treatment of lung adenocarcinoma.Virology · 2008Article
- Implications of micro-RNA profiling for cancer diagnosis.Oncogene · 2006Review
- Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.Genes & development · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mutations of proto-oncogenes are common events in the pathogenesis of cancers, as shown in a wide range of studies during the 30 years since the discovery of these genes. The benefits of novel therapies that target the products of mutant alleles in human cancers, and the demonstrated dependence of cancers in mouse models on continued expression of initiating oncogenes, are especially promising signs that revolutionary improvements in cancer care are possible. Full realization of the promise of targeted therapies, however, will require better definitions of the genotypes of human cancers, new approaches to interrupt the biochemical consequences of oncogenic mutations, and a greater understanding of drug resistance and tumor progression. In this paper, we summarize recent efforts toward these goals in our laboratory and others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.